Legend Biotech
LEGN
Legend Biotech (LEGN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.09
- EPS estimate
- $0.06
- EPS surprise
- +59.86%
- Revenue surprise
- +8.86%
- Revenue
- $387.5M
- Revenue estimate
- $356.0M
- Reported
- Aug 11, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | $0.06 | $0.09 | +59.86% | $387.5M | SEC |
| Q1 2026 | May 12, 2026 | $0.01 | −$0.15 | −1319.51% | $305.1M | SEC |
| Q4 2025 | Mar 10, 2026 | $0.00 | −$0.08 | −16100.00% | $306.3M | SEC |
| Q3 2025 | Nov 12, 2025 | −$0.07 | −$0.11 | −51.31% | $272.3M | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.11 | −$0.34 | −199.56% | $255.1M | SEC |
| Q1 2025 | May 13, 2025 | −$0.21 | −$0.27 | −28.33% | $195.1M | SEC |
| Q4 2024 | Mar 11, 2025 | −$0.25 | $0.07 | +128.29% | $186.5M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.33 | −$0.34 | −3.12% | $160.2M | SEC |
| Q2 2024 | Aug 9, 2024 | −$0.29 | −$0.05 | +82.60% | $186.5M | SEC |
| Q1 2024 | May 13, 2024 | −$0.19 | −$0.16 | +17.31% | $94.0M | SEC |
| Q4 2023 | Mar 11, 2024 | −$0.36 | −$0.40 | −12.49% | $79.5M | SEC |
| Q3 2023 | Nov 20, 2023 | −$0.31 | −$0.17 | +45.18% | $96.0M | SEC |
| Q2 2023 | Aug 15, 2023 | −$0.36 | −$0.57 | −57.94% | $73.3M | SEC |
| Q1 2023 | May 18, 2023 | −$0.42 | −$0.34 | +18.56% | $36.3M | SEC |
| Q4 2022 | Mar 30, 2023 | −$0.38 | −$0.32 | +16.47% | $27.5M | SEC |
| Q3 2022 | Invalid Date | −$0.37 | −$0.37 | +0.88% | $27.5M | — |
| Q2 2022 | Invalid Date | −$0.31 | −$0.35 | −12.83% | $15.2M | — |
| Q1 2022 | Jun 1, 2022 | −$0.36 | −$0.13 | +63.72% | $40.8M | — |
| Q4 2021 | Mar 18, 2022 | −$0.34 | −$0.30 | +12.23% | $39.0M | — |
| Q3 2021 | Nov 16, 2021 | −$0.42 | −$0.43 | −3.46% | $16.9M | — |
Quarterly revenue
Frequently asked questions
When did Legend Biotech (LEGN) last report earnings?
Legend Biotech last reported on Aug 11, 2026, covering fiscal Q2 2026.
Did LEGN beat earnings estimates?
Yes. Legend Biotech reported EPS of $0.09 for Q2 2026 against a $0.06 estimate — a 59.86% beat.
How much revenue did LEGN report last quarter?
Legend Biotech reported $387.5M in revenue for Q2 2026, against a consensus estimate of $356.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.